1.49 0 (0%) | 03-28 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 1.95 | 1-year : | 2.21 |
Resists | First : | 1.67 | Second : | 1.89 |
Pivot price | 1.5 | |||
Supports | First : | 1.29 | Second : | 1.08 |
MAs | MA(5) : | 1.48 | MA(20) : | 1.47 |
MA(100) : | 1.61 | MA(250) : | 1.6 | |
MACD | MACD : | 0 | Signal : | 0 |
%K %D | K(14,3) : | 23.9 | D(3) : | 24.6 |
RSI | RSI(14): 49.6 | |||
52-week | High : | 3.25 | Low : | 0.92 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ OKYO ] has closed above bottom band by 45.7%. Bollinger Bands are 43.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
If tomorrow: | Open lower | Open higher |
High: | 1.52 - 1.53 | 1.53 - 1.53 |
Low: | 1.42 - 1.44 | 1.44 - 1.45 |
Close: | 1.47 - 1.49 | 1.49 - 1.5 |
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Mon, 25 Mar 2024
OKYO Pharma Ltd expected to post a loss of 11 cents a share - Earnings Preview - XM
Sat, 23 Mar 2024
OKYO Pharma (NASDAQ:OKYO) Price Target Raised to $7.00 at HC Wainwright - Defense World
Sat, 23 Mar 2024
OKYO Pharma (LON:OKYO) Stock Price Down 24.3% - Defense World
Fri, 22 Mar 2024
OKYO Pharma says OK-101 shows statistically significant improvements for dry eye symptoms - Proactive Investors USA
Fri, 22 Mar 2024
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of ... - Yahoo Finance
Thu, 21 Mar 2024
OKYO Pharma to host event featuring Phase 2 trial results for OK-101 in dry eye disease - Proactive Investors USA
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 33 (M) |
Held by Insiders | 1.364e+007 (%) |
Held by Institutions | 25.7 (%) |
Shares Short | 51 (K) |
Shares Short P.Month | 0 (K) |
EPS | -1.318e+007 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -173.5 % |
Return on Equity (ttm) | -2 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | -0.15 |
Sales Per Share | 0 |
EBITDA (p.s.) | -0.28 |
Qtrly Earnings Growth | -0.7 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -8 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | 0 |
Price to Cash Flow | 59.04 |
Dividend | 0 |
Forward Dividend | 64630 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |